Priyanka Verma,
- Assistant Research Officer, Regional Research Institute of Unani Medicine, New Delhi, India
Abstract
Neurasthenia, referred to as Zof-e-Asaab in the Unani system of medicine, is a functional disorder characterized by generalized weakness of the nervous system. Individuals suffering from this condition commonly experience persistent fatigue, reduced physical and mental performance, low mood, irritability, disturbed sleep, and, in some cases, elevated blood pressure. Although various conventional treatment options are available for symptom management, no specific curative therapy has been established. Furthermore, long-term use of certain modern medications may be associated with undesirable adverse effects, highlighting the need for safer and more effective therapeutic alternatives. Unani medicine offers a holistic approach to health and emphasizes the use of natural formulations that have traditionally been considered safe and well tolerated. The present study was undertaken to evaluate the safety of the Unani pharmacopoeial formulation Majoon-e-Lana in patients diagnosed with neurasthenia (Zof-e-Asaab). Eligible participants were screened according to predefined diagnostic criteria before enrollment. Baseline clinical assessment was performed, and fasting blood samples were collected for laboratory investigations. Participants received Majoon-e-Lana at a dose of 5 g twice daily with plain water after meals for a treatment period of six weeks. To monitor the safety profile of the formulation, biochemical parameters, including liver function tests (LFTs) and kidney function tests (KFTs), were evaluated at baseline and after completion of the intervention. Clinical observations and laboratory findings were carefully analyzed throughout the study period. No serious adverse events or clinically significant abnormalities were observed during treatment. Based on these findings, Majoon-e-Lana appeared to be well tolerated and demonstrated a favorable safety profile, suggesting that it is safe for human consumption and may serve as a potential supportive therapeutic option for the management of neurasthenia.
Keywords: Neurasthenia, Validation Study, Zof–e-Asaab, Clinical Trial.
Priyanka Verma. Evaluation of Safety of Unani Pharmacopieal Majoon-e-Lana in Cases of Neurasthenia. Research & Reviews : A Journal of Unani, Siddha and Homeopathy. 2026; 13(02):-.
Priyanka Verma. Evaluation of Safety of Unani Pharmacopieal Majoon-e-Lana in Cases of Neurasthenia. Research & Reviews : A Journal of Unani, Siddha and Homeopathy. 2026; 13(02):-. Available from: https://journals.stmjournals.com/rrjoush/article=2026/view=248109
References
1. Aghanouri Z, Mojahedi M, Montazeri A, Siavash M. Reply to “Methodological notes, should be considered in research on Mizaj”. Journal of Research in Medical Sciences. 2021 Jan 1;26(1):8.
2. Farahani AM, Rezapour M, Shirafkan H. Methodological notes, should be considered in research on mizaj. Journal of Research in Medical Sciences. 2021 Jan 1;26(1):7.
3. Azmi A. A, Basic Concepts of Unani Medicine-A Critical Study, 1st Edition, Department of History of Medicine, Jamia Hamdard, New Delhi, 1995, pp. 65-68.
4. Brain R Walker, Nicki R College. Davidson’s Principles and practice of Medicine 22nd.Edition, 2015.Churchill Livingstone Elsevier. p.246
5. Kasper DL, Fauci AS, Hauser SL, Longo DL, Jameson JL, Loscalzo J.2015.Harrison’s Principles of Internal Medicine, 19th Edition,(Volume 1 and 2),p.2703.
6. Lee MH, Kim Y, Cho SH. Review on diagnostic criteria of neurasthenia: Suggesting pathway of culture-bound dieases. Journal of Pharmacopuncture. 2017 Nov 21;20(4):230.
7. Qarshi M Hasan.2011.Jam-ul Hikmat. Idara Kitab Us Shifa. p. 420-426.
8. Tang W, Gao Y, Chen G, Gao H, Dai X, Ye J, Chan E, Huang M, Zhou S. A randomized, double-blind and placebo-controlled study of a Ganoderma lucidum polysaccharide extract in neurasthenia. Journal of medicinal food. 2005 Mar;8(1):53-8.
9. Khan AS, Ansari SA, Devi U, Ahmed MW, Ahmed A. Evaluation of Pharmacopeial Standards and HPTLC Profile of Classical Unani Formulation-Majoon-e-Lana. Homeopathy. 2002:1.
10. Alam S, Anjum N. Importance of Tinospora Cordifolia (Giloy) and Zingiber Officinale (Ginger) and Their Traditional Knowledge, Chemical Derivatives, and Potential Profit, Especially in Alzheimer’s and Parkinson’s Diseases. InMedicinal Plants for the Management of Neurodegenerative Diseases 2024 Jun 17 (pp. 182-197). CRC Press.
Research & Reviews : A Journal of Unani, Siddha and Homeopathy
| Volume | 13 | |
| 02 | ||
| Received | 26/02/2026 | |
| Accepted | 15/06/2026 | |
| Published | 16/06/2026 | |
| Publication Time | 110 Days |